{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis+Relapse&page=7", "query": { "condition": "Multiple Sclerosis Relapse", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 439, "total_pages": 44, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis+Relapse&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis+Relapse&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:52:20.489Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03650114", "title": "Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Tetanus toxoid (TT) containing vaccine (Td, Tdap)", "type": "BIOLOGICAL" }, { "name": "13-valent pneumococcal conjugate vaccine (13-PCV)", "type": "BIOLOGICAL" }, { "name": "23-valent pneumococcal polysaccharide vaccine (23-PPV)", "type": "BIOLOGICAL" }, { "name": "Seasonal Quadrivalent influenza vaccine", "type": "BIOLOGICAL" }, { "name": "Keyhole limpet hemocyanin (KLH) neo-antigen", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1882, "start_date": "2018-12-28", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650114" }, { "nct_id": "NCT06444113", "title": "Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ofatunumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 24, "start_date": "2024-11-25", "completion_date": "2026-10-29", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 4, "location_summary": "San Francisco, California • Aurora, Colorado • Winfield, Illinois + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Winfield", "state": "Illinois" }, { "city": "Brookline", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06444113" }, { "nct_id": "NCT00112723", "title": "Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Multiple Myeloma", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2005-12", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2016-08-08", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112723" }, { "nct_id": "NCT04458688", "title": "Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Observation of Ocrelizumab as Treatment in RRMS Patients", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wayne State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 80, "start_date": "2021-11-20", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2022-06-06", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458688" }, { "nct_id": "NCT02255656", "title": "Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Relapsing Remitting Multiple Sclerosis" ], "interventions": [ { "name": "alemtuzumab GZ402673", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1062, "start_date": "2015-01-07", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 52, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02255656" }, { "nct_id": "NCT04909502", "title": "Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Forms of Multiple Sclerosis" ], "interventions": [ { "name": "EHP-101 25 mg OD", "type": "DRUG" }, { "name": "EHP-101 25 mg BID", "type": "DRUG" }, { "name": "EHP-101 50 mg OD", "type": "DRUG" }, { "name": "EHP-101 50 mg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emerald Health Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 50, "start_date": "2021-10-19", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2022-10-21", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 3, "location_summary": "Cullman, Alabama • Fullerton, California • Port Orange, Florida", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Port Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04909502" }, { "nct_id": "NCT02440126", "title": "Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "Rocky Mountain MS Research Group, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2014-10", "completion_date": "2020-07", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02440126" }, { "nct_id": "NCT06526000", "title": "Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Relapsing Multiple Sclerosis", "Clinically Isolated Syndrome", "Relapsing-remitting Multiple Sclerosis", "Secondary Progressive Multiple Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2022-10-11", "completion_date": "2024-02-28", "has_results": false, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06526000" }, { "nct_id": "NCT01332019", "title": "Long-Term Safety and Efficacy Study of Peginterferon Beta-1a", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "peginterferon beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1077, "start_date": "2011-04", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Lexington, Kentucky • Baltimore, Maryland + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Akron", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332019" }, { "nct_id": "NCT01970410", "title": "MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "teriflunomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "21 Years to 60 Years" }, "enrollment_count": 55, "start_date": "2013-10", "completion_date": "2022-02-14", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-11-15T12:52:20.489Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Latham, New York • Portland, Oregon", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Latham", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01970410" } ] }